CHRNA7 and inflammatory bowel disease: The evidence supporting the reversal of LPS-mediated inflammation through the potentiation of α7-nAChR could have major implications for enhancing the efficacy of anticancer treatments and addressing diseases such as inflammatory bowel disease, for which there is still no safe remedy to alleviate.